Please try another search
PHAXIAM Therapeutics S.A., a biopharmaceutical company, focuses on developing treatments for resistant bacterial infections in France and the United States. It develops eryaspase, which is in Phase 3 clinical development for the treatment of second-line pancreatic cancer, and in Phase 2 stage for the treatment of triple-negative breast cancer and second-line acute lymphoblastic leukemia patients. The company also engages in developing a portfolio of phages targeting resistant and dangerous bacteria, which together account for more than two-thirds of resistant hospital-acquired infections, including staphylococcus aureus, escherichia coli, and pseudomonas aeruginosa. The company was formerly known as ERYTECH Pharma S.A. and changed its name to PHAXIAM Therapeutics S.A. in June 2023. PHAXIAM Therapeutics S.A. was incorporated in 2004 and is headquartered in Lyon, France.
Name | Age | Since | Title |
---|---|---|---|
Philippe Archinard | 64 | 2013 | Independent Director |
Hilde Windels | 58 | 2014 | Independent Director |
Gil Beyen | 61 | 2013 | Vice Chairman |
Didier Hoch | - | 2023 | Chairman of the Board |
Leila Nicolas | 44 | 2023 | Representative Director |
Robert Sebbag | - | 2023 | Independent Director |
Valerie Faillat | - | 2024 | Independent Director |
Guy Rigaud | 77 | 2023 | Board Censor |
Eric Raymond | - | 2009 | Consultant & Member of Scientific Board |
Philip L. Lorenzi | - | 2010 | Consultant & Member of Scientific Board |
Bridget Bax | - | 2012 | Consultant & Member of Scientific Board |
Arthur E. Frankel | - | 2012 | Consultant & Member of Scientific Board |
Kurt C. Gunter | 69 | 2012 | Consultant & Member of Scientific Board |
Olivier Martinez | 51 | 2024 | Board Censor |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review